Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed Mycosis fungoides: SWOG 1108 Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Azepines
  • Lymphoma, T-Cell, Peripheral
  • Mycosis Fungoides
  • Pyrimidines

abstract

  • Alisertib has antitumor activity in PTCL, including heavily pretreated patients. These promising results are being further investigated in an ongoing international, randomized phase III trial comparing alisertib with investigator's choice in PTCL.

publication date

  • July 20, 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4500834

Digital Object Identifier (DOI)

  • 10.1200/JCO.2014.60.6327

PubMed ID

  • 26077240

Additional Document Info

start page

  • 2399

end page

  • 404

volume

  • 33

number

  • 21